colorectal cancer
Conditions
Interventions
adjuvant Xeloda followed by XELOX total 5 course after curative resection of liver metastasis from colorectal carcinoma.
Sponsors
Kobe City Medical Center General Hospital
Kobe City Medical Center West Hospital,Nishikobe Medical Center,Takarazuka city hospital,Himeji red cross hospital,Nishinomiya Hospital et al.
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1)histlogically proven colorectal carcinoma 2)Curatively resected metastatic liver tumors form colorectal cancer 3)No extrahepatic sites of disease 4)wihtin 90 days from the date of liver resection 5)age >= 20 years 6)Performance status must be Eastern Cooperative Oncology Group (ECOG) 0, or 1 7)No prior chemotherapy and radiotherapy to the liver 8)Adequate bone marrow, hepatic, renal, cardiac and respiratory functions 9)Written informed consent
Exclusion criteria
Exclusion criteria: 1) active synchronous or metachronous malignancy other than carcinoma in situ 2) pregnant or nursing 3) severe mental disorders 4) systemic steroid user 5) diabetes mellitus, uncontrolled or controlled with insulin 6) history of myocardial infarction, unstable angina within 3 months prior to the registration 7) serious coexisting illness 8) active infection 9) peripheral neuropathy greater than Grade 2
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| completion rate of adjuvant chemotherapy | — |
Secondary
| Measure | Time frame |
|---|---|
| OS,PFS,AE,recurrence,dose-intensity | — |
Countries
Japan
Contacts
Public ContactHironaga Satake
Kobe City Medical Center General Hospital medical oncology
Outcome results
None listed